Evaluation of drug-induced neurotoxicity based on metabolomics, proteomics and electrical activity measurements in complementary CNS in vitro models

Toxicology in Vitro

Volumn 30, Issue 1, 2015, Pages 138-165

  Schultz, Luise ^a   Zurich, Marie Gabrielle ^b   Culot, Maxime ^c   da Costa, Anaelle ^c   Landry, Christophe ^c   Bellwon, Patricia ^d   Kristl, Theresa ^e   Hörmann, Katrin ^e   Ruzek, Silke ^e   Aiche, Stephan ^f   Reinert, Knut ^f   Bielow, Chris ^f   Gosselet, Fabien ^c   Cecchelli, Romeo ^c   Huber, Christian G ^e   Schroeder, Olaf H U ^g   Gramowski Voss, Alexandra ^a,g   Weiss, Dieter G ^a,g   Bal Price, Anna ^h  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITÉ D'ARTOIS   (France)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e UNIVERSITY OF SALZBURG   (Austria)

^f FREIE UNIVERSITÄT BERLIN   (Germany)

^g NEUROPROOF GMBH   (Germany)

^h JOINT RESEARCH CENTRE   (Italy)

Author keywords

3D brain culture; Drug development; In vitro blood brain barrier; MEA; Neuronal network culture; OMICs

Indexed keywords

AMIODARONE; CHLORPROMAZINE; CYCLOSPORIN A; DIAZEPAM; NEUROTOXIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CELL CULTURE; BRAIN LEVEL; CELL AGGREGATION; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DOWN REGULATION; ELECTRIC ACTIVITY; EMBRYO; FRONTAL CORTEX; GLIAL CELL CULTURE; IN VITRO STUDY; METABOLOMICS; NERVE CELL NETWORK; NEUROTOXICITY; NONHUMAN; PATTERN RECOGNITION; PREDICTION; PROTEOMICS; RAT; TOXICITY TESTING; ANIMAL; BIOLOGICAL MODEL; CELL CULTURE; DOSE RESPONSE; DRUG EFFECTS; ELECTROPHYSIOLOGY; NERVE CELL; NEUROTOXICITY SYNDROMES; PHYSIOLOGY;

ANIMALS; BLOOD-BRAIN BARRIER; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGICAL PHENOMENA; METABOLOMICS; MODELS, BIOLOGICAL; NEURONS; NEUROTOXICITY SYNDROMES; NEUROTOXINS; PROTEOMICS; RATS;

EID: 84930920752     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2015.05.016     Document Type: Article

References (112)

1. Agid Y., Buzsaki G., Diamond D.M., Frackowiak R., Giedd J., et al. How can drug discovery for psychiatric disorders be improved?. Nat. Rev. Drug Discov. 2007, 6:189-201.
2. Bal-Price A., Brown G.C. Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J. Neurosci. 2001, 21:6480-6491.
3. Bal-Price A.K., Hogberg H.T., Buzanska L., Coecke S. Relevance of in vitro neurotoxicity testing for regulatory requirements: challenges to be considered. Neurotoxicol. Teratol. 2010, 32:36-41.
4. Bal-Price A.K., Coecke S., Costa L., Crofton K.M., Fritsche E., et al. Advancing the science of developmental neurotoxicity (DNT): testing for better safety evaluation. ALTEX 2012, 29:202-215.
5. Bal-Price A., Crofton K.M., Sachana M., Shafer T.J., Behl M., et al. Putative adverse outcome pathways (AOP) relevant to neurotoxicity. Crit. Rev. Toxicol. 2015, 45(1):83-91.
6. Bal-Price A., Crofton Kevin, Leist Marcel, Allen Sandra, Arand Michael, et al. International STakeholder NETwork (ISTNET): creating a Developmental Neurotoxicity (DNT) testing roadmap for regulatory purposes. Arch. Toxicol. 2015, 89:269-287.
7. Balasz, M., Szkilnik, R., Brus, R., Malinowska-Borowska, J., Kasperczyk, S., et al. 2014. Perinatal manganese exposure and hydroxyl radical formation in rat brain. Neurotoxicity research.
8. Becker S., Liu X. Evaluation of the utility of brain slice methods to study brain penetration. Drug Metab. Dispos.: Biol. Fate Chem. 2006, 34:855-861.
9. Bellwon P., Culot M., Wilmes A., Schmidt T., Zurich M., et al. Cyclosporine A kinetics in brain cell cultures and its potential of crossing the blood-brain barrier. Toxicol. In Vitro 2015, 30:166-175.
10. Boveri M., Kinsner A., Berezowski V., Lenfant A.M., Draing C., et al. Highly purified lipoteichoic acid from gram-positive bacteria induces in vitro blood-brain barrier disruption through glia activation: role of pro-inflammatory cytokines and nitric oxide. Neuroscience 2006, 137:1193-1209.
11. Booher J., Sensenbrenner M. Growth and cultivation of dissociated neurons and glial cells from embryonic chick, rat and human brain in flask cultures. Neurobiology 1972, 2:97-105.
12. Breitwieser F.P., Muller A., Dayon L., Kocher T., Hainard A., et al. General statistical modeling of data from protein relative expression isobaric tags. J. Proteome Res. 2011, 10:2758-2766.
13. Cao P., Maximov A., Sudhof T.C. Activity-dependent IGF-1 exocytosis is controlled by the Ca(2+)-sensor synaptotagmin-10. Cell 2011, 145:300-311.
14. Cecchelli R., Dehouck B., Descamps L., Fenart L., Buee-Scherrer V.V., et al. In vitro model for evaluating drug transport across the blood-brain barrier. Adv. Drug Deliv. Rev. 1999, 36:165-178.
15. Cecchelli R., Aday S., Sevin E., Almeida C., Culot M., et al. A stable and reproducible human blood-brain barrier model derived from hematopoietic stem cells. PloS one 2014, 9:e99733.
16. Chapman E.R. Synaptotagmin: a Ca(2+) sensor that triggers exocytosis?. Nat. Rev. Mol. Cell Biol. 2002, 3:498-508.
17. Choi D.W., Viseskul V., Amirthanayagam M., Monyer H. Aspartate neurotoxicity on cultured cortical neurons. J. Neurosci. Res. 1989, 23:116-121.
18. Coecke S., Ahr H., Blaauboer B.J., Bremer S., Casati S., et al. Metabolism: a bottleneck in in vitro toxicological test development. The report and recommendations of ECVAM workshop 54. Altern. Lab. Animals: ATLA 2006, 34:49-84.
19. Coecke S., Eskes C., Gartlon J., Kinsner A., Price A., et al. The value of alternative testing for neurotoxicity in the context of regulatory needs. Environ. Toxicol. Pharmacol. 2006, 21:153-167.
20. Craig R., Beavis R.C. TANDEM: matching proteins with tandem mass spectra. Bioinformatics 2004, 20:1466-1467.
21. Cremona O., Di Paolo G., Wenk M.R., Luthi A., Kim W.T., et al. Essential role of phosphoinositide metabolism in synaptic vesicle recycling. Cell 1999, 99:179-188.
22. Crofton K.M., Mundy W.R., Lein P.J., Bal-Price A., Coecke S., et al. Developmental neurotoxicity testing: recommendations for developing alternative methods for the screening and prioritization of chemicals. ALTEX 2011, 28:9-15.
23. Csermely P., Korcsmaros T., Kiss H.J., London G., Nussinov R. Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review. Pharmacol. Therap. 2013, 138:333-408.
24. Culot M., Lundquist S., Vanuxeem D., Nion S., Landry C., et al. An in vitro blood-brain barrier model for high throughput (HTS) toxicological screening. Toxicol. In Vitro: Int. J. Publ. Assoc. BIBRA 2008, 22:799-811.
25. Culot M., Fabulas-da Costa A., Sevin E., Szorath E., Martinsson S., et al. A simple method for assessing free brain/free plasma ratios using an in vitro model of the blood brain barrier. PloS one 2013, 8:e80634.
26. Cummings J.L., Morstorf T., Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimer's Res. Therapy 2014, 6:37.
27. Defranchi E., Novellino A., Whelan M., Vogel S., Ramirez T., et al. Feasibility assessment of micro-electrode chip assay as a method of detecting neurotoxicity in vitro. Front. Neuroeng. 2011, 4:6.
28. Dehouck M.P., Meresse S., Delorme P., Fruchart J.C., Cecchelli R. An easier, reproducible, and mass-production method to study the blood-brain barrier in vitro. J. Neurochem. 1990, 54:1798-1801.
29. Eyal A., Szargel R., Avraham E., Liani E., Haskin J., et al. Synphilin-1A: an aggregation-prone isoform of synphilin-1 that causes neuronal death and is present in aggregates from alpha-synucleinopathy patients. Proc. Natl. Acad. Sci. USA 2006, 103:5917-5922.
30. Fabulas-da Costa A., Aijjou R., Hachani J., Landry C., Cecchelli R., Culot M. In vitro blood-brain barrier model adapted to repeated-dose toxicological screening. Toxicol. In Vitro: Int. J. Publ. Assoc. BIBRA 2013, 27:1944-1953.
31. Frega M., Pasquale V., Tedesco M., Marcoli M., Contestabile A., et al. Cortical cultures coupled to micro-electrode arrays: a novel approach to perform in vitro excitotoxicity testing. Neurotoxicol. Teratol. 2012, 34:116-127.
32. Friden M., Gupta A., Antonsson M., Bredberg U., Hammarlund-Udenaes M. In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids. Drug Metab. Dispos.: Biol. Fate Chem. 2007, 35:1711-1719.
33. Fridman J.S., Lowe S.W. Control of apoptosis by p53. Oncogene 2003, 22:9030-9040.
34. Fung M., Thornton A., Mybeck K., Wu J.H.-H., Hornbuckle K., Muniz E. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets-1960 to 1999. Drug Inform. J. 2001, 35:293-317.
35. Geer L.Y., Markey S.P., Kowalak J.A., Wagner L., Xu M., et al. Open mass spectrometry search algorithm. J. Proteome Res. 2004, 3:958-964.
36. Gramowski A., Jugelt K., Weiss D.G., Gross G.W. Substance identification by quantitative characterization of oscillatory activity in murine spinal cord networks on microelectrode arrays. Eur. J. Neurosci. 2004, 19:2815-2825.
37. Gramowski A., Jugelt K., Stuwe S., Schulze R., McGregor G.P., et al. Functional screening of traditional antidepressants with primary cortical neuronal networks grown on multielectrode neurochips. Eur. J. Neurosci. 2006, 24:455-465.
38. Gramowski A., Flossdorf J., Bhattacharya K., Jonas L., Lantow M., et al. Nanoparticles induce changes of the electrical activity of neuronal networks on microelectrode array neurochips. Environ. Health Perspect. 2010, 118:1363-1369.
39. Gramowski A., Jugelt K., Schroder O.H., Weiss D.G., Mitzner S. Acute functional neurotoxicity of lanthanum(III) in primary cortical networks. Toxicol. Sci.: Off. J. Soc. Toxicol. 2011, 120:173-183.
40. Gross G., Gopal K. Emerging histiotypic properties of cultured neuronal networks. Advances in Network Electrophysiology 2006, 193-214. Springer, US. M. Taketani, M. Baudry (Eds.).
41. Gross G.W., Rhoades B.K., Reust D.L., Schwalm F.U. Stimulation of monolayer networks in culture through thin-film indium-tin oxide recording electrodes. J. Neurosci. Meth. 1993, 50:131-143.
42. Gross G.W., Harsch A., Rhoades B.K., Gopel W. Odor, drug and toxin analysis with neuronal networks in vitro: extracellular array recording of network responses. Biosensors Bioelectron. 1997, 12:373-393.
43. Hakimi M.A., Bochar D.A., Chenoweth J., Lane W.S., Mandel G., Shiekhattar R. A core-BRAF35 complex containing histone deacetylase mediates repression of neuronal-specific genes. Proc. Natl. Acad. Sci. USA 2002, 99:7420-7425.
44. Hallier-Vanuxeem D., Prieto P., Culot M., Diallo H., Landry C., et al. New strategy for alerting central nervous system toxicity: integration of blood-brain barrier toxicity and permeability in neurotoxicity assessment. Toxicol. In Vitro: Int. J. Publ. Assoc. BIBRA 2009, 23:447-453.
45. Hansen J.M., Carney E.W., Harris C. Altered differentiation in rat and rabbit limb bud micromass cultures by glutathione modulating agents. Free Radical Bio. Med. 2001, 31:1582-1592.
46. Harry G.J., Tiffany-Castiglioni E. Evaluation of neurotoxic potential by use of in vitro systems. Expert Opin. Drug Metab. Toxicol. 2005, 1:701-713.
47. Hassel B., Dingledine R. Glutamate. Basic Neurochemistry: Molecular, Cellular and Medical Aspects 2006, 268-290. Elsevier Academic Press. S. Brady, G. Siegel, R.W. Albers, D. Price (Eds.).
48. Hodel A. SNAP-25. Int. J. Biochem. Cell Biol. 1998, 30:1069-1073.
49. Hogberg H.T., Sobanski T., Novellino A., Whelan M., Weiss D.G., Bal-Price A.K. Application of micro-electrode arrays (MEAs) as an emerging technology for developmental neurotoxicity: evaluation of domoic acid-induced effects in primary cultures of rat cortical neurons. Neurotoxicology 2011, 32:158-168.
50. Honegger P., Zurich M.G. Preparation and use of serum-free aggregating brain cell cultures for routine neurotoxicity screening. Cell Culture Techniques 2011, 105-128. Humana Press, New York. M. Aschner, C. Suñol, A. Bal-Price (Eds.).
51. Honegger P., Lenoir D., Favrod P. Growth and differentiation of aggregating fetal brain cells in a serum-free defined medium. Nature 1979, 282:305-308.
52. Huettner J.E., Baughman R.W. Primary culture of identified neurons from the visual cortex of postnatal rats. J. Neurosci.: Off. J. Soc. Neurosci. 1986, 6:3044-3060.
53. Johnstone A.F., Gross G.W., Weiss D.G., Schroeder O.H., Gramowski A., Shafer T.J. Microelectrode arrays: a physiologically based neurotoxicity testing platform for the 21st century. Neurotoxicology 2010, 31:331-350.
54. Judson R., Kavlock R., Martin M., et al. Perspectives on validation of high-throughput assays supporting 21st century toxicity testing. ALTEX 2013, 30:51-56.
55. Kalvass J.C., Maurer T.S. Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm. Drug Dispos. 2002, 23:327-338.
56. Keefer E.W., Gramowski A., Gross G.W. NMDA receptor-dependent periodic oscillations in cultured spinal cord networks. J. Neurophysiol. 2001, 86:3030-3042.
57. Kirschner M.A., Arriza J.L., Copeland N.G., Gilbert D.J., Jenkins N.A., et al. The mouse and human excitatory amino acid transporter gene (EAAT1) maps to mouse chromosome 15 and a region of syntenic homology on human chromosome 5. Genomics 1994, 22:631-633.
58. Kleinjans, J., 2014. Toxicogenomics-based Cellular Models. Alternatives to Animal Testing for Safety Assessment. MA, USA.
59. Kleinstreuer N.C., Smith A.M., West P.R., Conard K.R., Fontaine B.R., et al. Identifying developmental toxicity pathways for a subset of ToxCast chemicals using human embryonic stem cells and metabolomics. Toxicology and applied pharmacology 2011, 257:111-121.
60. Koh J.Y., Choi D.W. Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay. J. Neurosci. Meth. 1987, 20:83-90.
61. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 2004, 3:711-715.
62. Lafuente-Lafuente C., Alvarez J.-C., Leenhardt A., Mouly S., Extramiana F., et al. Amiodarone concentrations in plasma and fat tissue during chronic treatment and related toxicity. British J. Clin. Pharmacol. 2009, 67:511-519.
63. Landesmann B., Mennecozzi M., Berggren E., Whelan M. Adverse outcome pathway-based screening strategies for an animal-free safety assessment of chemicals. Altern. Lab. Animals: ATLA 2013, 41:461-471.
64. Lefew W.R., McConnell E.R., Crooks J.L., Shafer T.J. Evaluation of microelectrode array data using Bayesian modeling as an approach to screening and prioritization for neurotoxicity testing. Neurotoxicology 2013, 36:34-41.
65. Leist M., Hasiwa N., Rovida C., et al. Consensus report on the future of animal-free systemic toxicity testing. ALTEX 2014, 31:341-356.
66. Mack C.M., Lin B.J., Turner J.D., Johnstone A.F., Burgoon L.D., Shafer T.J. Burst and principal components analyses of MEA data for 16 chemicals describe at least three effects classes. Neurotoxicology 2014, 40:75-85.
67. McConnell E.R., McClain M.A., Ross J., Lefew W.R., Shafer T.J. Evaluation of multi-well microelectrode arrays for neurotoxicity screening using a chemical training set. Neurotoxicology 2012, 33:1048-1057.
68. Meldrum B.S. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J. Nutr. 2000, 130:1007s-1015s.
69. Meresse S., Dehouck M.P., Delorme P., Bensaid M., Tauber J.P., et al. Bovine brain endothelial cells express tight junctions and monoamine oxidase activity in long-term culture. J. Neurochem. 1989, 53:1363-1371.
70. Monnet-Tschudi F., Zurich M.G., Asher R., Honegger P. Glial hyaluronate-binding protein expression in aggregating brain cell cultures. Develop. Neurosci. 1993, 15:395-402.
71. Monnet-Tschudi F., Zurich M.G., Honegger P. Neurotoxicant-induced inflammatory response in three-dimensional brain cell cultures. Hum. Exp. Toxicol. 2007, 26:339-346.
72. Montesinos R.N., Moulari B., Gromand J., Beduneau A., Lamprecht A., Pellequer Y. Coadministration of P-glycoprotein modulators on loperamide pharmacokinetics and brain distribution. Drug Metab. Dispos.: Biol. Fate Chem. 2014, 42:700-706.
73. Nahnsen S., Bertsch A., Rahnenfuhrer J., Nordheim A., Kohlbacher O. Probabilistic consensus scoring improves tandem mass spectrometry peptide identification. J. Proteome Res. 2011, 10:3332-3343.
74. Namikawa K., Asakura M., Minami T., Okazaki Y., Kadota E., Hashimoto S. Toxicity of cisplatin to the central nervous system of male rabbits. Biol. Trace Element Res. 2000, 74:223-235.
75. Nemes P., Rubakhin S.S., Aerts J.T., Sweedler J.V. Qualitative and quantitative metabolomic investigation of single neurons by capillary electrophoresis electrospray ionization mass spectrometry. Nat. Protocols 2013, 8:783-799.
76. Novellino A., Scelfo B., Palosaari T., Price A., Sobanski T., et al. Development of micro-electrode array based tests for neurotoxicity: assessment of interlaboratory reproducibility with neuroactive chemicals. Front. Neuroeng. 2011, 4:4.
77. Parenti C., Turnaturi R., Arico G., Gramowski-Voss A., Schroeder O.H., et al. The multitarget opioid ligand LP1's effects in persistent pain and in primary cell neuronal cultures. Neuropharmacology 2013, 71:70-82.
78. Perkins D.N., Pappin D.J., Creasy D.M., Cottrell J.S. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 1999, 20:3551-3567.
79. Petralia R.S., Wang Y.X., Niedzielski A.S., Wenthold R.J. The metabotropic glutamate receptors, mGluR2 and mGluR3, show unique postsynaptic, presynaptic and glial localizations. Neuroscience 1996, 71:949-976.
80. Pistollato F., Bremer-Hoffmann S., Healy L., Young L., Stacey G. Standardization of pluripotent stem cell cultures for toxicity testing. Expert Opin. Drug Metab. Toxicol. 2012, 8:239-257.
81. Platt S.R. The role of glutamate in central nervous system health and disease - a review. Veterinary J. 2007, 173:278-286. (London, England: 1997).
82. Pompella A., Visvikis A., Paolicchi A., De Tata V., Casini A.F. The changing faces of glutathione, a cellular protagonist. Biochem. Pharmacol. 2003, 66:1499-1503.
83. Pomponio G., Zurich M., Schultz L., Weiss D.G., Romanelli L., et al. Amiodarone biokinetics in brain cell cultures and the formation of its major oxidative metabolite after repeated exposure. Toxicol. In Vitro: Int. J. Publ. Assoc. BIBRA 2015.
84. Ransom B.R., Neale E., Henkart M., Bullock P.N., Nelson P.G. Mouse spinal cord in cell culture. I. Morphology and intrinsic neuronal electrophysiologic properties. J. Neurophysiol. 1977, 40:1132-1150.
85. Regenthal R., Krueger M., Koeppel C., Preiss R. Drug levels: therapeutic and toxic serum/plasma concentrations of common drugs. J. Clin. Monit. Comput. 1999, 15:529-544.
86. Riedmiller M, Braun H. 1993. Neural networks, IEEE International Conference on 1993. 1, 586-591.
87. Robinette B.L., Harrill J.A., Mundy W.R., Shafer T.J. In vitro assessment of developmental neurotoxicity: use of microelectrode arrays to measure functional changes in neuronal network ontogeny. Front. Neuroeng. 2011, 4:1-10.
88. Rovida C., Alépée N., Api A.M., Basketter D.A., Bois F.Y., et al. Integrated Testing Strategies (ITS) for safety assessment. ALTEX 2015, 32(1):25-40.
89. Sadeque A.J., Wandel C., He H., Shah S., Wood A.J. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin. Pharmacol. Therap. 2000, 68:231-237.
90. Schinkel A.H., Wagenaar E., Mol C.A., van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 1996, 97:2517-2524.
91. Schuster D., Laggner C., Langer T. Why drugs fail - a study on side effects in new chemical entities. Curr. Pharma. Des. 2005, 11:3545-3559.
92. Shafer T.J., Rijal S.O., Gross G.W. Complete inhibition of spontaneous activity in neuronal networks in vitro by deltamethrin and permethrin. Neurotoxicology 2008, 29:203-212.
93. Sieber M., Hoffmann D., Adler M., Vaidya V.S., Clement M., et al. Comparative analysis of novel noninvasive renal biomarkers and metabonomic changes in a rat model of gentamicin nephrotoxicity. Toxicol. Sci.: Off. J. Soc. Toxicol. 2009, 109:336-349.
94. Siflinger-Birnboim A., Del Vecchio P.J., Cooper J.A., Blumenstock F.A., Shepard J.M., Malik A.B. Molecular sieving characteristics of the cultured endothelial monolayer. J. Cell. Physiol. 1987, 132:111-117.
95. Smirnova L., Hogberg H.T., Leist M., Hartung T. Developmental neurotoxicity - challenges in the 21st century and in vitro opportunities. ALTEX 2014, 31:129-156.
96. Sturm M., Bertsch A., Gropl C., Hildebrandt A., Hussong R., et al. OpenMS - an open-source software framework for mass spectrometry. BMC Bioinform. 2008, 9:163.
97. Sugimoto S., Yamamoto Y.L., Nagahiro S., Diksic M. Permeability change and brain tissue damage after intracarotid administration of cisplatin studied by double-tracer autoradiography in rats. J. Neuro-oncol. 1995, 24:229-240.
98. Tyan S.H., Shih A.Y., Walsh J.J., Maruyama H., Sarsoza F., et al. Amyloid precursor protein (APP) regulates synaptic structure and function. Mol. Cell. Neurosci. 2012, 51:43-52.
99. Valdivia P., Martin M., LeFew W.R., Ross J., Houck K.A., Shafer T.J. Multi-well microelectrode array recordings detect neuroactivity of ToxCast compounds. Neurotoxicology 2014, 44:204-217.
100. van Vliet E., Morath S., Eskes C., Linge J., Rappsilber J., et al. A novel in vitro metabolomics approach for neurotoxicity testing, proof of principle for methyl mercury chloride and caffeine. Neurotoxicology 2008, 29:1-12.
101. Vandormael B., Fourla D.D., Gramowski-Voss A., Kosson P., Weiss D.G., et al. Superpotent [Dmt(1)] dermorphin tetrapeptides containing the 4-aminotetrahydro-2-benzazepin-3-one scaffold with mixed mu/delta opioid receptor agonistic properties. J. Med. Chem. 2011, 54:7848-7859.
102. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature 2000, 408:307-310.
103. Wanek T., Mairinger S., Langer O. Radioligands targeting P-glycoprotein and other drug efflux proteins at the blood-brain barrier. J. Label. Comp. Radiopharma. 2013, 56:68-77.
104. Wang H., Qian W.J., Mottaz H.M., Clauss T.R., Anderson D.J., et al. Development and evaluation of a micro- and nanoscale proteomic sample preparation method. J. Proteome Res. 2005, 4:2397-2403.
105. Waterman-Storer C.M., Karki S.B., Kuznetsov S.A., Tabb J.S., Weiss D.G., et al. The interaction between cytoplasmic dynein and dynactin is required for fast axonal transport. Proc. Natl. Acad. Sci. USA 1997, 94:12180-12185.
106. Weiss D.G. Neurotoxicity assessment by recording electrical activity from neuronal networks on microelectrode array neurochips. Cell Culture Techniques 2011, 467-480. Humana Press, New York. M. Aschner, C. Suñol, A. Bal-Price (Eds.).
107. West P.R., Weir A.M., Smith A.M., Donley E.L., Cezar G.G. Predicting human developmental toxicity of pharmaceuticals using human embryonic stem cells and metabolomics. Toxicol. Appl. Pharm. 2010, 247:18-27.
108. Wilmes A., Limonciel A., Aschauer L., Moenks K., Bielow C., et al. Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress. J. Proteomics 2013, 79:180-194.
109. Zhao W., Mosley B.S., Cleves M.A., Melnyk S., James S.J., Hobbs C.A. Neural tube defects and maternal biomarkers of folate, homocysteine, and glutathione metabolism. Birth defects research Part A. Clin. Mol. Teratol. 2006, 76:230-236.
110. Zurich M.G., Honegger P. Ochratoxin A at nanomolar concentration perturbs the homeostasis of neural stem cells in highly differentiated but not in immature three-dimensional brain cell cultures. Toxicol. Lett. 2011, 205:203-208.
111. Zurich, M., Bal-Price, A., 2015. Potential biomarkers of neurotoxicity identified by transcriptomics analyses in 3D rat brain aggregating cultures after repeated exposure to 12 drugs (in preparation).
112. Zurich M.-G., Stanzel S., Kopp-Schneider A., Prieto P., Honegger P. Evaluation of aggregating brain cell cultures for the detection of acute organ-specific toxicity. Toxicol. In Vitro 2013, 27:1416-1424.